Citation Impact
Citing Papers
Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer
2003 Standout
Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study
2000 Standout
Protein Misfolding, Amyloid Formation, and Human Disease: A Summary of Progress Over the Last Decade
2017 Standout
Randomized Phase III Study of Surgery Alone or Surgery Plus Preoperative Cisplatin and Gemcitabine in Stages IB to IIIA Non–Small-Cell Lung Cancer
2011
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
2008 Standout
Meta-Analysis of Concomitant Versus Sequential Radiochemotherapy in Locally Advanced Non–Small-Cell Lung Cancer
2010 Standout
Gemcitabine in combination with trastuzumab and/or platinum salts in breast cancer cells with HER2 overexpression.
2004
Rational Combinations of Trastuzumab With Chemotherapeutic Drugs Used in the Treatment of Breast Cancer
2004
A Combination of Chemoimmunotherapies Can Efficiently Break Self-Tolerance and Induce Antitumor Immunity in a Tolerogenic Murine Tumor Model
2007 StandoutNobel
ERBB receptors and cancer: the complexity of targeted inhibitors
2005 Standout
Recent advances in the management of AL Amyloidosis
2015
Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group
2007 Standout
Glutathione S-conjugates as prodrugs to target drug-resistant tumors
2014
Platinum-based chemotherapy in metastatic breast cancer: current status
2003
Quantification of mRNA using real-time RT-PCR
2006 Standout
Biological functions of fucose in mammals
2017
Induction of resistance to the multitargeted antifolate Pemetrexed (ALIMTA) in WiDr human colon cancer cells is associated with thymidylate synthase overexpression
2003
Clinical translation of angiogenesis inhibitors
2002 Standout
A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum
1998
Antitumor diarylsulfonylureas: novel agents with unfulfilled promise
1996
Role of Gemcitabine in Breast Cancer Management: An Update
2006
ERS/ESTS clinical guidelines on fitness for radical therapy in lung cancer patients (surgery and chemo-radiotherapy)
2009 Standout
Role of platelet-derived growth factors in physiology and medicine
2008 Standout
Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2016 Standout
Docetaxel (Taxotere) shows survival and quality-of-life benefits in the second-line treatment of non-small cell lung cancer: A review of two phase III trials
2001
Chemotherapy-Induced Ca2+ Release Stimulates Breast Cancer Stem Cell Enrichment
2017 StandoutNobel
Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future
2017 Standout
A phase II study of gemcitabine in platinum pre-treated patients with advanced epithelial ovarian cancer
1998
Developing new metal-based therapeutics: challenges and opportunities
2007
Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity
2004 Standout
Dose Escalation of Gemcitabine Is Possible With Concurrent Chest Three-Dimensional Rather Than Two-Dimensional Radiotherapy: A Phase I Trial in Patients With Stage III Non–Small-Cell Lung Cancer
2008
Gemcitabine Plus Cisplatin for the Treatment of Metastatic Breast Cancer
2002
Soft-Tissue Sarcomas in Adults
2005 Standout
Weekly docetaxel in the treatment of elderly patients with advanced nonsmall cell lung carcinoma
2000
The role of new agents in the treatment of non-small cell lung cancer
2002
Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: a phase II study.
1997
Chemotherapy-Induced Anemia in Adults: Incidence and Treatment
1999
Trastuzumab — Mechanism of Action and Use in Clinical Practice
2007 Standout
Gemcitabine and paclitaxel associated pneumonitis in non-small cell lung cancer
2000
Cellular processing of platinum anticancer drugs
2005 Standout
Pemetrexed plus Platinum as the First-Line Treatment Option for Advanced Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials
2012
Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2017 Standout
Reverse transcriptase template switching during reverse transcriptase–polymerase chain reaction: Artificial generation of deletions in ribonucleotide reductase mRNA
2001
2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours
2010 Standout
New trends for metal complexes with anticancer activity
2008 Standout
Randomized phase II trial of gefitinib or gemcitabine or docetaxel chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2 or 3 (IFCT-0301 study)
2010
In vitro cross-resistance and collateral sensitivity in seven resistant small-cell lung cancer cell lines: preclinical identification of suitable drug partners to taxotere, taxol, topotecan and gemcitabin
1997
Clinical-benefit response in advanced non-small-cell lung cancer: A multicentre prospective randomised phase III study of single agent gemcitabine versus cisplatin–vindesine
2001
Evaluation of Factors Related to Late Recurrence - Later than 10 Years after the Initial Treatment - in Primary Breast Cancer
2013 Standout
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
2010 Standout
Hypoxia-inducible factors promote breast cancer stem cell specification and maintenance in response to hypoxia or cytotoxic chemotherapy
2018 StandoutNobel
Macrophages as regulators of tumour immunity and immunotherapy
2019 Standout
Pulmonary toxicity in patients treated with gemcitabine plus vinorelbine or docetaxel for advanced non-small cell lung cancer: outcome data on a randomized phase II study
2007
Bioreductive activation and drug chaperoning in cobalt pharmaceuticals
2007
Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial
2010 Standout
Role of gemcitabine in cancer therapy
2005
Microtubules as a target for anticancer drugs
2004 Standout
A phase II trial testing gemcitabine as second-line chemotherapy for non small cell lung cancer
2000
Multiple-Treatments Meta-analysis of Chemotherapy and Targeted Therapies in Advanced Breast Cancer
2008
Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial
2001
Treatment of Non-Small-Cell Lung Cancer With Prolonged Oral Etoposide
1998
Cisplatin in cancer therapy: Molecular mechanisms of action
2014 Standout
Phase II Trial of Gemcitabine plus Trastuzumab in Metastatic Breast Cancer Patients Previously Treated with Chemotherapy: Preliminary Results
2002
Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2
2001 Standout
Second-line chemotherapy with gemcitabine and carboplatin in paclitaxel-pretreated, platinum-sensitive ovarian cancer patients A Hellenic Cooperative Oncology Group Study
2003
Gemcitabine in advanced adult soft-tissue sarcomas. A phase II study of the EORTC Soft Tissue and Bone Sarcoma Group
2002
The anti-angiogenic basis of metronomic chemotherapy
2004 Standout
Treatment of Breast Cancer
1998
Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies
2006 Standout
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2018 Standout
Phase II study of pemetrexed in combination with carboplatin in the first‐line treatment of advanced nonsmall cell lung cancer
2005
Engineered Nanoparticles for Drug Delivery in Cancer Therapy
2014 Standout
Gemcitabine
1997
Advances in Malignant Mesothelioma
2005 Standout
Anemia of Chronic Disease
2005 Standout
Small RNAs are modified with N-glycans and displayed on the surface of living cells
2021 StandoutNobel
A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer
2005
Gemcitabine Plus Paclitaxel Versus Paclitaxel Monotherapy in Patients With Metastatic Breast Cancer and Prior Anthracycline Treatment
2008
Biochemical Modulation of Cisplatin Mechanisms of Action: Enhancement of Antitumor Activity and Circumvention of Drug Resistance
2003 Standout
Gemcitabine and Docetaxel in Patients With Unresectable Leiomyosarcoma: Results of a Phase II Trial
2002
Coordinating Radiometals of Copper, Gallium, Indium, Yttrium, and Zirconium for PET and SPECT Imaging of Disease
2010 Standout
Identification, Molecular Cloning, and Analysis of Full-Length Hepatitis C Virus Transmitted/Founder Genotypes 1, 3, and 4
2015 StandoutNobel
Phase II Study of ET-743 in Advanced Soft Tissue Sarcomas: A European Organisation for the Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group Trial
2005 Standout
Gemcitabine and Cisplatin Versus Mitomycin, Ifosfamide, and Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Randomized Phase III Study of the Italian Lung Cancer Project
1999
Monotherapy options in the management of metastatic breast cancer
2003
Fluorine and Fluorinated Motifs in the Design and Application of Bioisosteres for Drug Design
2018 Standout
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
2011 Standout
Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma
2003 Standout
Synthesis and Cytotoxic Evaluation of Substituted Sulfonyl-N-hydroxyguanidine Derivatives as Potential Antitumor Agents
1997
The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations
2015 Standout
Pemetrexed Combined with Oxaliplatin or Carboplatin as First-Line Treatment in Advanced Non–Small Cell Lung Cancer: A Multicenter, Randomized, Phase II Trial
2005
Phase I and Pharmacokinetic Study of Imatinib Mesylate (Gleevec) and Gemcitabine in Patients with Refractory Solid Tumors
2007
Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy
2004 Standout
Gemcitabine, paclitaxel, and trastuzumab in metastatic breast cancer.
2001
Leptomeningeal disease: current diagnostic and therapeutic strategies
2017
A phase I and pharmacokinetic study of ILX-295501, an oral diarylsulfonylurea, on a weekly for 3 weeks every 4-week schedule in patients with advanced solid malignancies.
2003
Combination therapy in combating cancer
2017 Standout
Phase II Study of Pegylated Liposomal Doxorubicin in Combination With Gemcitabine in Patients With Metastatic Breast Cancer
2003
Single-agent gemcitabine: an active and better tolerated alternative to standard cisplatin-based chemotherapy in locally advanced or metastatic non-small cell lung cancer
1999
Recurrent Epithelial Ovarian Carcinoma: A Randomized Phase III Study of Pegylated Liposomal Doxorubicin Versus Topotecan
2001 Standout
Systemic amyloidosis: novel therapies and role of biomarkers
2016
Docetaxel in combination with gemcitabine plus rhG-CSF support as second-line treatment in non-small cell lung cancer. A multicenter phase II study
2001
Advances in Copper Complexes as Anticancer Agents
2013 Standout
CSF-1R–Dependent Lethal Hepatotoxicity When Agonistic CD40 Antibody Is Given before but Not after Chemotherapy
2016
Randomized Phase III Study of Gemcitabine-Cisplatin Versus Etoposide-Cisplatin in the Treatment of Locally Advanced or Metastatic Non–Small-Cell Lung Cancer
1999
American Society of Clinical Oncology Treatment of Unresectable Non–Small-Cell Lung Cancer Guideline: Update 2003
2003 Standout
Novel sulphonamide derivatives for the treatment of cancer
2000
Works of Jackie Walling being referenced
First-in-Human Phase I/II Study of NEOD001 in Patients With Light Chain Amyloidosis and Persistent Organ Dysfunction
2016
A phase II study of sulofenur, a novel sulfonylurea, in recurrent epithelial ovarian cancer
1992
A phase II study of sulofenur (LY186641) in gastric cancer
1992
Chemotherapy for advanced non-small-cell lung cancer
1994
A phase I study of a 24 hour infusion of gemcitabine in previously untreated patients with inoperable non-small-cell lung cancer
1996
Phase II trial of the novel sulphonylurea sulofenur in advanced breast cancer
1993
Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: a phase II study.
1994
Advanced breast cancer: a phase II trial with gemcitabine.
1995
Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy.
2002
A Phase I Study Of KB004, a Novel Non-Fucosylated humaneered® Antibody, Targeted Against The Receptor Tyrosine Kinase EphA3, In Advanced Hematologic Malignancies
2013
A phase I study of gemcitabine and carboplatin in non-small cell lung cancer.
1996
Cardiac and renal biomarker responses in a phase 1/2 study of NEOD001 in patients with AL amyloidosis and persistent organ dysfunction.
2015